Yoshihiro Ashihara
President chez Fuji SC Bio KK
Profil
Yoshihiro Ashihara is currently the Director at Fujirebio, Inc. since 2018, the Director at Fujirebio Europe NV since 2010, and the President & Representative Director at Fuji SC Bio KK since 2005.
In the past, he held positions as Director at Fujirebio Diagnostics, Inc., President & Representative Director at Advanced Life Science Institute KK, Director at Fujirebio America, Inc., and Executive Officer, Head-Research & Development at H.U.
Group Holdings, Inc.
Postes actifs de Yoshihiro Ashihara
| Sociétés | Poste | Début |
|---|---|---|
| Fuji SC Bio KK | President | 01/03/2005 |
Fujirebio, Inc.
 Fujirebio, Inc. Medical SpecialtiesHealth Technology Fujirebio, Inc. engages in the manufacture, sale, import and export of clinical diagnostic reagents and assay instruments. It also provides diagnostic, clinical laboratory testing and related services. The company was founded on December 18, 1950 and is headquartered in Tokyo, Japan. | Directeur/Membre du Conseil | 01/06/2009 |
Fujirebio Europe NV
 Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Directeur/Membre du Conseil | 01/09/2010 |
Anciens postes connus de Yoshihiro Ashihara
| Sociétés | Poste | Fin |
|---|---|---|
| Fujirebio America, Inc. | Directeur/Membre du Conseil | - |
Fujirebio Diagnostics, Inc.
 Fujirebio Diagnostics, Inc. Medical SpecialtiesHealth Technology Fujirebio Diagnostics, Inc. develops, manufactures and commercializes in-vitro diagnostic products. Its products include oncology RIA and EIA kits, veterinary products and research kits. The company was founded in 1965 and is headquartered in Malvern, PA | Directeur/Membre du Conseil | - |
Advanced Life Science Institute KK
 Advanced Life Science Institute KK Pharmaceuticals: MajorHealth Technology Advanced Life Science Institute KK manufactures and wholesales testing drugs for hepatitis viruses and lung cancers. The company is based in Tokyo, Japan and was founded in 1997. | President | - |
| H.U. GROUP HOLDINGS, INC. | Directeur Technique/Scientifique/R&D | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| H.U. GROUP HOLDINGS, INC. | Health Services |
| Entreprise privées | 6 |
|---|---|
Fujirebio Diagnostics, Inc.
Fujirebio Diagnostics, Inc. Medical SpecialtiesHealth Technology Fujirebio Diagnostics, Inc. develops, manufactures and commercializes in-vitro diagnostic products. Its products include oncology RIA and EIA kits, veterinary products and research kits. The company was founded in 1965 and is headquartered in Malvern, PA | Health Technology |
| Fuji SC Bio KK | |
Advanced Life Science Institute KK
Advanced Life Science Institute KK Pharmaceuticals: MajorHealth Technology Advanced Life Science Institute KK manufactures and wholesales testing drugs for hepatitis viruses and lung cancers. The company is based in Tokyo, Japan and was founded in 1997. | Health Technology |
| Fujirebio America, Inc. | |
Fujirebio, Inc.
Fujirebio, Inc. Medical SpecialtiesHealth Technology Fujirebio, Inc. engages in the manufacture, sale, import and export of clinical diagnostic reagents and assay instruments. It also provides diagnostic, clinical laboratory testing and related services. The company was founded on December 18, 1950 and is headquartered in Tokyo, Japan. | Health Technology |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Health Technology |